Characteristic | Low-Dose (n = 313) | Full-Dose (n = 2624) | Adjusted Odds Ratioa to Receive Low-dose DOAC | 95% Confidence Interval | p-value |
---|---|---|---|---|---|
Age (yrs) | |||||
 ≤ 69 | 31.6% | 41.0% | REF |  |  |
 70–74 | 24.6% | 31.7% | 1.01 | (0.72, 1.39) | 0.97 |
 75–79 | 43.8% | 27.2% | 2.09 | (1.56, 2.81) | <  0.001 |
Gender | |||||
 Female | 1.0% | 0.5% | 1.98 | (0.42, 6.78) | 0.32 |
 Male | 99.0% | 99.5% | REF |  |  |
Race | |||||
 White | 78.6% | 78.9% | REF |  |  |
 Black | 14.7% | 15.3% | 0.92 | (0.64, 1.30) | 0.64 |
 Other | 6.7% | 5.8% | 1.11 | (0.65, 1.81) | 0.68 |
Geographic Region | |||||
 Northeast | 10.9% | 11.4% | REF |  |  |
 Midwest | 17.3% | 24.9% | 0.69 | (0.44, 1.11) | 0.12 |
 West | 18.8% | 19.9% | 0.83 | (0.52, 1.33) | 0.43 |
 South | 53.0% | 43.9% | 1.15 | (0.78, 1.75) | 0.50 |
Weight, kg | |||||
 61–69 | 13.1% | 3.8% | 3.76 | (2.45, 5.70) | <  0.001 |
 70–79 | 12.1% | 10.7% | 1.18 | (0.79, 1.72) | 0.41 |
 80+ | 74.8% | 85.4% | REF |  |  |
Key Comorbid Conditionsb | |||||
 Heart Failure | 34.8% | 31.1% | 1.12 | (0.84, 1.47) | 0.44 |
 Hypertension | 86.3% | 84.8% | 1.13 | (0.74, 1.75) | 0.59 |
 Vascular Disease | 31.0% | 28.2% | 1.16 | (0.87, 1.53) | 0.31 |
 Diabetes | 70.9% | 70.1% | 0.96 | (0.70, 1.32) | 0.80 |
 Prior Bleeding | 6.1% | 4.7% | 1.20 | (0.69, 1.99) | 0.50 |
 Stroke | 11.2% | 9.0% | 1.09 | (0.72, 1.62) | 0.66 |
Creatinine Categories (%), in mg/dL | |||||
 1.50–1.59 | 13.7% | 23.2% | REF |  |  |
 1.60–1.79 | 23.6% | 31.0% | 1.33 | (0.88, 2.02) | 0.18 |
 ≥1.80 | 62.6% | 45.8% | 2.51 | (1.76, 3.69) | <  0.001 |
Elixhauser Comorbidities | |||||
 0–2 | 13.1% | 12.3% | REF |  |  |
 3–4 | 27.2% | 32.8% | 0.70 | (0.44, 1.13) | 0.14 |
 ≥ 5 | 55.0% | 50.4% | 0.82 | (0.50, 1.38) | 0.46 |